Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Intas Pharmaceuticals

    Tag: intas pharmaceuticals

    You Searched For "Intas Pharmaceuticals"
    Intas Contributes two million tablets of hydroxychloroquine for  Global Trials Against COVID-19

    Intas Contributes two million tablets of hydroxychloroquine for Global Trials Against COVID-19

    Medical Dialogues Bureau3 April 2020 10:15 AM IST
    Intas will provide up to two million tablets of hydroxychloroquine to the trial, free of charge, along with two million tablets of matched placebo.
    Bevetex Vs Bevatas: Delhi HC junks Sun Pharma arm plea against Intas Pharma over trademark

    Bevetex Vs Bevatas: Delhi HC junks Sun Pharma arm plea against Intas Pharma over trademark

    Farhat Nasim9 Feb 2020 11:30 AM IST
    New Delhi: In a major setback to drug giant Sun Pharmaceuticals Ltd.'s arm, Sun Pharma Laboratories Ltd., the Delhi high court has recently dismissed...
    Over Rs 74 crore fine on Himalaya, Intas Pharma, 2 Chemist Associations for anti-competitive trade practices

    Over Rs 74 crore fine on Himalaya, Intas Pharma, 2 Chemist Associations for anti-competitive trade practices

    Medical Dialogues Bureau8 Jun 2019 2:35 PM IST
    As per the CCI order, Himalaya Drug was fined Rs 18.59 crore while its three senior officials were fined a total of nearly Rs 4 lakh. Besides, Intas...
    Intas Pharma cuts down price of cancer drug Bevacizumab by 60 percent

    Intas Pharma cuts down price of cancer drug Bevacizumab by 60 percent

    Ruby Khatun Khatun6 Oct 2017 11:12 AM IST
    AHMEDABAD: Intas Pharmaceuticals Limited, announced that the company is cutting down the cost of the cancer drug Bevacizumab by 60 percent in order to...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok